Company Encyclopedia
View More
name
Telomir Pharmaceuticals
TELO.US
Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on reversing biological aging and degenerative diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Progeria, Wilson’s disease, and age-related macular degeneration (amd), as well as type 2 diabetes, cancer, and Alzheimer’s disease. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc.
4.668 T
TELO.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Telomir-1 Lowers PSA Levels and Reduces Tumor Volume in Prostate Cancer Studies

    Telomir Pharmaceuticals Inc. announced preclinical data showing Telomir-1 reduces PSA levels and tumor volume in prostate cancer studies. Telomir-1 lowers PSA in a dose-dependent manner and reduces cellular energy metabolism and viability. In mouse models, it reduced tumor volume alone and with paclitaxel, without treatment-related mortality. The company is preparing for an IND submission. The announcement was made via EDGAR by Telomir Pharmaceuticals.

    Reuters·
    US
    TELO
    -1.41%
    Reuters·
    US
    TELO
    -1.41%

    Telomir Pharmaceuticals Director Craig Eagle Resigns

    Craig Eagle has resigned from the Board of Directors of Telomir Pharmaceuticals Inc., effective immediately. This information was published by Telomir Pharmaceuticals via the EDGAR system on November 20, 2025.

    Reuters·
    US
    TELO
    -1.41%
    Reuters·
    US
    TELO
    -1.41%

    Telomir Pharmaceuticals Inc. Announces Date for Upcoming Virtual Annual Meeting of Stockholders

    Telomir Pharmaceuticals Inc. will hold its Annual Meeting online via live audio-only webcast on December 30, 2025. Stockholders will vote on various proposals related to the company's business and operations. The original content was published via EDGAR by Telomir Pharmaceuticals Inc. on November 20, 2025.

    Reuters·
    US
    TELO
    -1.41%
    Reuters·
    US
    TELO
    -1.41%

    Telomir-1 Kills Aggressive Human Leukemia Cells in Preclinical Study

    Telomir Pharmaceuticals Inc. announced that its investigational compound, Telomir-1, effectively kills aggressive human leukemia cells in vitro. The study shows Telomir-1 reduces leukemia cell viability in a dose-dependent manner and lowers intracellular iron levels, crucial for leukemia cell growth. It also inhibits histone-demethylase enzymes and reduces abnormal DNA methylation of tumor-suppressor genes, expanding its oncology profile to include blood cancers. This supports further oncology research by the company.

    Reuters·
    US
    TELO
    -1.41%
    Reuters·
    US
    TELO
    -1.41%

    Telomir Pharmaceuticals Unveils Promising Preclinical Data

    Telomir Pharmaceuticals, Inc. (TELO) has released promising preclinical data showing that its compound, Telomir-1, effectively reduces intracellular iron levels in human keratinocytes, outperforming the FDA-approved iron chelator Deferoxamine. This discovery suggests Telomir-1's potential in addressing oxidative stress and epigenetic regulation, which are linked to aging and diseases. Analysts rate TELO stock as a Buy with a $15.00 price target. The company focuses on developing treatments for metal-ion balance and cellular health, with a current market cap of $47.1M.

    Tip Ranks·
    US
    TELO
    -1.41%
    Tip Ranks·
    US
    TELO
    -1.41%
    © 2025 Longbridge｜Disclaimer